UCB : Transparency notification UCB SA/NV

Brussels (Belgium), 20 January 2020 - 20:10 (CET) - regulated information
1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has filed a transparency notification.

The transparency notification dated 20 January 2020 has been submitted in accordance with Article 18 juncto Article 6 of the law of 2 May 2007 on the disclosure of large shareholdings, due to UCB covering its obligations towards employees in the framework of the Long Term Incentive plans of the UCB group. As a result thereof, voting rights relating to voting securities held by UCB SA/NV and its affiliates crossed downwards the 3% threshold on 17 January 2020.

On 17 January 2020, UCB SA/NV (taking into account the holding of its affiliates) owned 5 742 539 UCB shares with voting rights (versus 5 975 516 UCB shares in its previous notification dated 12 March 2019), representing 2.95% of the total number of shares issued by the company (194 505 658) (versus 3.07% in the notification dated 12 March 2019).

2. Content of the notification

• Reason for the notification:
  - Acquisition or disposal of voting securities or voting rights
  - Downwards crossing of the lowest threshold
• Notification by: A parent undertaking or a controlling person.
• Person subject to the notification requirement:

• Date on which the threshold is crossed : 17 January 2020
• Threshold crossed (in %): 3%
• Denominator: 194 505 658
• Notified details:

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following link.

Investor Relations
Antje Witte

Investor Relations, UCB
T +32.2.559.94.14 [e-mail]

Isabelle Ghellynck,Investor Relations, UCBT+32.2.559.9588, [e-mail]
About UCBUCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news